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ABSTRACT
Objectives: This study aims to investigate the factors associated with early discontinuation (within one year) of etanercept (ETA) in rheumatoid 
arthritis (RA) patients who began ETA as first biologic disease-modifying antirheumatic drug (bDMARD) and who were entered into the Gruppo 
Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis; GISEA) registry.
Patients and methods: This registry-based cohort study included 477 RA patients (95 males, 382 females; median age 53 years; range 18 to 83 years) 
who began ETA as first bDMARD. Patient demographics, disease features and drugs were re-evaluated after 12 months. Baseline predictors of ETA 
discontinuation were estimated by univariate and multivariate analyses using Cox regression model.
Results: Seventy patients (14.7%) discontinued ETA during the first year (for inefficacy in 55.8%, adverse events in 28.6%, and other reasons in 6.5%). 
Concurrent conventional synthetic DMARDs (csDMARDs) were reported in 54.3% of patients, mainly methotrexate (MTX), while 52.4% of subjects 
took low doses of glucocorticoids. Patients stopping ETA more frequently showed one or more comorbidities, mainly cardiovascular diseases (28.6% 
vs. 15.7% in patients stopping and continuing ETA, respectively, p=0.009). The presence of comorbidities and a combination therapy with csDMARDs 
other than MTX were independent factors associated with early discontinuation of ETA at multivariate Cox analysis.
Conclusion: Although ETA demonstrated a high persistence in biologic-naïve RA patients, about 15% of patients discontinued the treatment within 
12 months. The presence of comorbidities and a combination therapy with csDMARDs other than MTX were the main factors for an early withdrawal 
of the drug.
Keywords: Etanercept, predictive factors, rheumatoid arthritis, treatment failure.
Citation:
Sebastiani M, Manfredi A, Iannone F, Gremese E, Bortoluzzi A, Favalli E, et al. Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis 
From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. Arch Rheumatol 2020;35(x):i-vii.
Arch Rheumatolii
Tumor necrosis factor-alpha inhibitors (TNFi) 
are usually the first biologic drugs employed for 
the treatment of rheumatoid arthritis (RA) after 
the failure of conventional synthetic disease-
modifying antirheumatic drugs (csDMARDs).1 
Among them, etanercept (ETA), a recombinant 
soluble TNF-alpha receptor, was one of the first 
TNFi to become commercially available, along 
with adalimumab and infliximab, with almost 
20 years of experience in clinical practice.2
Adalimumab, ETA, and infliximab have 
shown similar high response rates in randomized 
controlled trials in terms of clinical efficacy and 
effect on joint damage progression;3-5 however, 
the non-selected patients encountered in everyday 
clinical practice often have more complex features 
than those enrolled in randomized controlled trials 
because of concomitant therapies, comorbidities, 
personal habits, and poor adherence, all of which 
may affect treatment success.1,2
Although many registry studies investigated 
the predictors of efficacy and persistence in TNFi 
therapy, such as age, clinical response to prior 
treatments with a TNFi, concomitant therapy 
with methotrexate (MTX), and the presence 
of comorbidities, few studies have evaluated 
the causes of early failure of these drugs.6-8 
Some analyses have focused on the causes of 
discontinuation of biologic DMARDs (bDMARDs) 
in long-term treatment,9,10 while, to our knowledge, 
no studies have searched for the factors associated 
to the failure of ETA in RA patients within the 
first year of therapy.
Given the recent introduction onto the market 
of new biologic and targeted synthetic drugs with 
different mechanisms of action, the profiling of 
patients with RA is strategic to identify patients 
with a lower possibility of response to therapy. 
Therefore, in this study, we aimed to investigate 
the factors associated with early discontinuation 
(within one year) of ETA in RA patients who 
began ETA as first bDMARD and who were 
entered into the Gruppo Italiano di Studio sulla 
Early Arthritis (Italian Group for the Study of 
Early Arthritis; GISEA) registry.
PATIENTS AND METHODS
The GISEA has developed and maintained 
a nationwide registry to promote the study 
of patients with rheumatic diseases who are 
being treated with biological drugs according to 
standard of care criteria.11 The registry involves 
21 hospitals and community-based rheumatology 
units throughout Italy and enrolls patients aged 
>18 years. The registry-based study was approved 
by the Hospital Ethics Committee of Modena 
(protocol number 2270, June 10th, 2015). A 
written informed consent was obtained from each 
patient. The study was conducted in accordance 
with the principles of the Declaration of Helsinki 
(as revised in Brazil 2013) and European and 
local rules of good clinical practice. In the GISEA 
registry, patient data are recorded at baseline, 
on prescribing of the bDMARD, and every six 
months thereafter (ClinicalTrials.gov identifier 
NCT01543594).
Rheumatoid arthritis was classified on the 
basis of the 1987 or 2010 American College 
of Rheumatology criteria.12 The data collected 
include age, sex, ethnicity, disease duration, 
time from diagnosis to beginning of treatment 
with a biological drug (latency), concurrent use 
of glucocorticoids and DMARD (namely MTX, 
leflunomide, sulphasalazine, hydroxychloroquine, 
cyclosporin A), smoking status, body mass index 
(BMI), the 28-joint disease activity score (DAS28), 
C-reactive protein levels, anti-citrullinated 
peptide antibodies (ACPAs), rheumatoid factor 
(RF), side effects and erythrocyte sedimentation 
rate (ESR; mm/hour). Comorbidities were 
recorded, including anemia, anxiety/depression, 
cardiovascular diseases (coronary artery diseases, 
chronic heart failure, arrhythmias), hypertension, 
cerebrovascular diseases, gastropathies, 
liver diseases, nephropathy, and peripheral 
vasculopathy, diabetes, chronic obstructive 
pulmonary diseases, and cancer. Information 
on extra-articular manifestations of patients’ 
rheumatic disease (Raynaud’s phenomenon, 
rheumatoid nodules, lung involvement, and sicca 
syndrome) was also collected.
The study included 477 RA patients (95 males, 
382 females; median age 53 years; range 18 
to 83 years) who began ETA as first bDMARD 
between 01 January 2001 and 31 December 
2016. Patients’ demographic, clinical and 
serological data, the intake of glucocorticoids and 
csDMARDs, extra-articular manifestations and 
comorbidities were recorded. Patients’ clinical 
status was re-evaluated after 12 months, with 
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a focus on disease activity and persistence with 
ETA therapy. When ETA was discontinued, the 
time and the cause of discontinuation were also 
recorded (i.e. lack or loss of efficacy, or adverse 
events). Time to discontinuation was defined as 
the time span between ETA initiation and the last 
administration plus one dispensation interval.
Statistical analysis
The differences between patients who stopped 
or continued ETA treatment within the first year 
of therapy were analyzed using the Mann-Whitney 
nonparametric test for continuous variables 
(median and interquartile ranges [IQRs]. The chi-
squared test was used for categorical variables 
(absolute numbers and percentages) regarding 
baseline characteristics. The univariate and 
multivariate analyses were performed using Cox 
regression model. Cox regression analysis was 
performed to analyze the effect of the baseline 
features of the patients on ETA discontinuation.
The baseline variables taken into account were 
sex, disease duration, comorbidities, DAS28, ESR, 
concurrent use of glucocorticoids and DMARDs, 
BMI, extra-articular manifestations, and smoking 
habit. Analyses were performed using the SAS 
software version 9.2 (SAS Institute Inc., Cary, 
NC, USA), with a p value <0.05 considered 
to be statistically significant. Unless otherwise 
indicated, the data are expressed as percentages 
or median (IQR).13
RESULTS
Four hundred and seventy-seven RA patients 
were included in the study [95 males, 382 females; 
median age 53 years (IQR: 18); range 18 to 83 
years; median disease duration of 5.4 years 
(IQR: 8.1), median DAS28 of 5.56 (IQR: 1.69), 
median swollen joints of 5 (IQR: 8) and median 
tender joints of 9 (IQR: 11)] (the other serological 
and clinical features were reported in Table 
1). RF and ACPAs were positive in 66% and 
62.3% of patients, respectively. Comorbidities 
were observed in 17.6% of patients, mainly 
cardiovascular diseases (9.6% of patients), arterial 
hypertension (11.6%), diabetes (1.9%), and chronic 
pulmonary obstructive diseases (2.1%), while 
extra-articular RA manifestations were recorded 
in 6.3%. Concurrent csDMARDs therapies were 
reported in 54.3% of patients, mainly MTX 
[40.5%, median dosage 10 (IQR 5) mg weekly], 
while 52.4% of patients took low doses of steroids. 
One hundred and twenty-nine patients (27%) took 
ETA alone, without csDMARDs or steroids.
Seventy patients (14.7%) discontinued ETA 
during the first year (for ineffectiveness in 
43 patients, adverse events in 22, and other 
reasons in five). ETA was stopped after a median 
of 23 weeks (range, 1-51 weeks).
The most frequent adverse events were 
represented by intolerance to the drug (skin 
reactions, fever after the injection, or malaise) 
in 21 patients, increase of liver enzymes in 
12 patients, and infections in 16; only two 
Table 1. Demographic, clinical and serological 
features of RA patients treated with etanercept as 
first-line biologic therapy (n=477)
n %
Gender
Female 382 80.1
Current smoker
Ex smoker
113
82
23.7
17.2
ACPA-positive 297 62.3
RF
ACPA + RF-positive
RF positive alone
ACPA-positive alone
None
315
257
58
40
122
66
53.9
12.2
8.4
25.6
Erythrocyte sedimentation rate 28 25
C-reactive protein >5 mg/L 323 67.7
Comorbidities
Cardiovascular diseases
Lung diseases
Liver diseases
Diabetes mellitus
84
46
10
5
9
17.6
9.6
2.1
1
1.9
Extra-articular manifestations
Rheumatoid nodules
Interstitial lung disease
Sjögren’s syndrome
Other
30
11
2
8
9
6.3
2.3
0.4
1.7
1.9
DMARDs
Methotrexate
Leflunomide
Hydroxycloroquine
Sulphasalazine
Cyclosporin A
259
193
40
16
6
4
54.3
40.5
8.4
3.3
1.3
0.8
Steroid therapy 250 52.4
RA: Rheumatoid arthritis; ACPA: Anti-citrullinated peptide antibody; 
RF: Rheumatoid factor; DMARDs: Disease-modifying anti-rheumatic 
drugs.
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patients had a major cardiovascular event (an acute 
myocardial infarction and a stroke).
Patients that discontinued ETA were more 
frequently treated with combination therapy 
(65.7% vs. 52.3%, p=0.038). In detail, 
the association with MTX did not increase 
maintenance in therapy, while patients 
treated with csDMARDs different from MTX 
discontinued ETA more frequently (24.3% 
vs. 12% in patients discontinuing or not 
discontinuing ETA, p=0.006) (Table 2). ETA 
monotherapy was more frequently recorded in 
patients that continued treatment (47.7% vs. 
34.3%, p=0.038). No differences were observed 
Table 2. Features of rheumatoid arthritis patients that continued or stopped etanercept within first year of therapy
Continuing etanercept (n=407) Stopping etanercept (n=70)
n % Median IQR n % Median IQR p
Age (years) 53 17 51 15 NS
Disease duration (years) 5.4 8.2 5.6 8 NS
Body mass index 24.5 5.8 25.4 6.3 NS
Erythrocyte sedimentation rate 28 23.2 28 35 NS
Tender joints 28 9 11 8 16 NS
Swollen joints 28 5 9 5 9 NS
Disease activity score in 28-joint 5.5 1.7 5.9 2.1 NS
Mean dosage of MTX (mg/week) 15 5 10 5 NS
Gender
Female 323 79.4 59 84.3 NS
Current smoker 98 24.2 15 21.8 NS
Rheumatoid factor positive 268 65.8 47 67.1 NS
ACPA positive
ACPA-RF positive
RF positive alone
ACPA-positive alone
None
249
219
49
30
109
61.2
53.8
12
7.4
26.8
48
38
9
10
13
68.6
54.3
12.9
14.3
18.6
NS
NS
NS
NS
NS
Co-morbidities 
Cardiovascular diseases
64
38
15.7
9.3
20
8
28.6
11.4
0.009
NS
Extra-articular manifestations 23 5.7 7 10 NS
Steroid therapy 210 51.6 40 57.1 NS
Etanercept monotherapy 194 47.7 24 34.3 0.038
DMARDs
Methotrexate
Other DMARDs
164
49
40.3
12
29
17
41.4
24.3
NS
0.006
C-Reactive protein (>5 mg/L) 277 68 46 65.7 NS
IQR: Interquartile range; MTX: Methotrexate; ACPA: Anti-citrullinated peptide antibody; RF: Rheumatoid factor; DMARD: Disease-modifying antirheumatic 
drug; NS: Not significant.
Table 3. Cause of failure of etanercept according to associated therapy
Inefficacy Adverse events Other
% % %
Methotrexate 72.4 20.7 6.9
Other csDMARDs 58.9 40.0 1.1
Etanercept monotherapy 50.0 37.5 12.5
csDMARDs: Conventional synthetic disease-modifying antirheumatic drugs; For every therapeutic strategy, 
table reports percentage of causes of discontinuation.
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in the median dosage of MTX in patients that 
continued or failed ETA.
Poor treatment efficacy was the main cause 
of discontinuation of ETA independently by the 
associated DMARD: 72.4% when associated with 
MTX, 58.9% with other csDMARDs, and 50% 
with monotherapy (Table 3).
Comparing patients that failed ETA according 
to the type of associated therapy, we observed 
higher rates of adverse events as the cause 
of discontinuation in patients treated with 
csDMARDs other than MTX and in monotherapy 
(40% and 37.5%, respectively), while only 20.7% 
of failure was due to side effects in patients treated 
with MTX (Table 3). No significant associations 
were observed with glucocorticoids, the presence 
of RF or ACPA or disease activity at baseline.
At multivariate Cox regression, the presence 
of comorbidities and a combination therapy with 
csDMARDs different from MTX were confirmed 
as independent factors associated with early 
discontinuation of ETA (Table 4).
DISCUSSION
The primary endpoint of our study was the 
analysis of the causes of early discontinuation 
(within the first year) of ETA in a real-world 
setting, observing a discontinuation rate of 14.7% 
during the first year of treatment.
The profiling of patients with RA is strategic 
in order to identify the correct therapeutic 
strategy. In this regard, the identification of 
patients with a lower possibility to respond to 
a single mechanism of action is relevant in the 
selection of the first-line therapy, to reduce 
switches to other drugs and to minimize the 
possibility of adverse events.
Several studies have analyzed the retention 
rate and the causes of discontinuation of 
bDMARDs during long-term treatment; however, 
to our knowledge, no studies have assessed the 
predictive factors related to the discontinuation of 
ETA in the first year of therapy, and only indirect 
data are available on this topic.7,8,10,14
In 2016, Chen et al.15 showed a 
discontinuation rate of 26.1% for ETA in the 
first year of therapy, with a lower risk compared 
to adalimumab, but without analyzing the causes 
of this finding. Chen et al.15 observed a higher 
rate of discontinuation compared to our data. 
In either study, the percentage of patients in 
combination therapy with MTX was about 40%, 
while in the population described by Chen et 
al.,15 a higher proportion of patients were treated 
with csDMARDs other than MTX, a possible 
factor associated with early discontinuation in 
our cohort.
Our data do not provide an explanation 
for the higher risk of ETA discontinuation in 
patients treated with csDMARDs other than MTX 
(i.e., lower efficacy, higher side effects, or reduced 
compliance) and only a few studies have explored 
this point.16 However, we cannot exclude that 
the low percentage of discontinuation for side 
effects in patients taking MTX could be due to a 
challenging bias, with a lower prescribing of MTX 
in patients with comorbidities.17
Several studies have shown contradictory 
results due to different methodologies, the study 
populations, and primary aims, namely long-
term retention rate rather than causes of early 
discontinuation.6,7,18-21
Of interest, monotherapy did not seem to be 
associated with a higher risk of discontinuation, 
nor did combination treatment with steroids 
modify the maintenance of ETA therapy. In this 
Table 4. Factors associated with early discontinuation of etanercept according 
to multivariate Cox regression analysis
Standard error Odds ratio 95% CI p
Comorbidities 0.28 1.86 1.07-3.25 0.029
DMARDs other than MTX 0.35 2.01 1.014-3.982 0.045
ETA monotherapy 0.297 0.701 0.392-1.256 0.232
CI: Confidence interval; DMARD: Disease-modifying antirheumatic drug; MTX: Methotrexate; ETA: 
Etanercept.
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regard, Favalli et al.7 in 2016 showed a higher 
retention rate in patients in combination therapy 
with ETA and MTX, but only in long-term 
treatments. Moreover, in our cohort, the presence 
of comorbidities was a significant factor associated 
with an early failure of ETA, similar to other Italian 
studies;18,19 however, other studies have described 
contradictory results, where the presence of 
associated diseases and the coadministration of 
csDMARDs (particularly MTX) were the best 
predictors of drug continuation in RA patients 
treated with TNFi.20 However, this study analyzed 
all TNFi together (ADA, ETA, INF), without sub-
analysis for individual drugs.20
Comorbidities were also associated with 
greater discontinuation rates in a Brazilian cohort 
of TNFi (±DMARD) users. On the other hand, in 
that study, the medication persistence rate at first 
year was 55.6% for ETA,20 much lower than in 
our Italian population.
Also, the role of BMI in the failure of 
TNFi is debated. Our study confirms previous 
observations showing that obesity does not 
reduce the maintenance of ETA therapy in RA 
patients. Similarly, in another cohort from the 
GISEA registry, a higher BMI was associated 
with a reduction of remission rate after one 
year in RA for patients treated with infliximab, 
but not with ETA or adalimumab.21 In contrast, 
in another Italian study, concomitant diseases 
positively predicted long-term TNFi continuation 
[odds ratio (OR) 0.6, p<0.01], even though no 
significant correlation with a single comorbidity 
was found.6 However, when multiple regression 
analysis was applied, the only baseline variable 
that significantly predicted drug survival at four 
years was DMARD intake (OR 0.64, p<0.05), 
with MTX having the highest significance (OR 
0.58, p<0.01).6
Kristensen et al.22 observed a one-year 
persistence on therapy of 89% for ETA when 
associated with MTX, while, when ETA was 
administered as monotherapy, the levels of 
adherence to therapy at one year was 74%. 
No significant differences were found when 
ETA was combined with other concomitant 
csDMARDs other than MTX. In the ETA group, 
total persistence in therapy was significantly 
higher for the subgroup receiving concomitant 
csDMARDs compared with ETA alone (p=0.015). 
Moreover, patients receiving ETA showed no 
differences in withdrawals because of adverse 
events when comparing combination therapy with 
monotherapy.
This study has some limitations. In particular, 
some comorbidities, such as cardiovascular 
diseases, include more conditions, namely 
coronary artery diseases, chronic heart failure, and 
arrhythmias that were not available individually. 
Moreover, functional damage and other conditions 
associated with pain (such as fibromyalgia) were 
not evaluated in this study, possibly influencing 
the efficacy of the treatment.
In conclusion, the identification of conditions 
associated with early failure of biologic or 
csDMARDs could assist in personalizing the 
therapeutic choice and reducing the frequency of 
switches of biologic drugs, decreasing the costs 
of the treatments for the national health services 
and the frequency of flare for the patients. Our 
results suggest that in clinical practice, careful 
attention should be paid to RA patients with 
comorbidities, in particular when a csDMARD 
other than MTX is associated with ETA. In these 
cases, a different biologic or targeting synthetic 
DMARD should be considered.
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